EMC10 Antibody

What is EMC10 and what are its key biological functions?

EMC10 is an evolutionarily conserved protein widely present in vertebrate species, including humans and mice, with 92% sequence homology between these species. It functions primarily as an angiogenic growth factor promoting tissue repair after myocardial infarction (MI) . EMC10 contains no known domains or motifs and has no homology with other proteins, making it a unique biological entity .

Functionally, EMC10 stimulates endothelial cell proliferation, network formation, and directed cell migration. It activates small GTPases (CDC42 and RAC1), which enhance directed cell migration by promoting the formation of filopodia and lamellipodia at the leading edge of cells . Downstream, EMC10 signals through p21-activated kinase (PAK) and the p38 mitogen-activated protein kinase (MAPK)–MAPK-activated protein kinase 2 (MK2) pathway to promote actin polymerization and cell migration .

What are the known isoforms of EMC10 and how do they differ structurally and functionally?

EMC10 exists in two main isoforms:

• EMC10-1 (previously known as HSM1): A single-pass type I membrane protein with its N-terminus protruding into the extracellular space.

• EMC10-2 (previously known as HSS1): A secreted protein that is released into the extracellular environment .

Both isoforms share the same N-terminal signal peptide and are processed via the classic secretory pathway. The key structural difference is that EMC10-1 contains a membrane-spanning domain that is absent in EMC10-2 .

Functionally, both isoforms promote angiogenic effects when expressed in endothelial cells, but only when they include their signal peptides, indicating that both must enter the secretory pathway to be biologically active. EMC10-1 appears to act in a juxtacrine manner (affecting adjacent cells), while EMC10-2 functions in a paracrine fashion .

How does EMC10 expression change in pathological conditions, particularly after myocardial infarction?

Following myocardial infarction, EMC10 expression increases significantly in the infarcted region of the left ventricle, with peak expression occurring approximately 3 days post-MI before declining thereafter. Importantly, this upregulation is localized to the infarcted region, with no significant induction observed in non-infarcted regions .

In addition to tissue expression, circulating (plasma) levels of EMC10 also increase 3 days after MI, suggesting potential systemic effects . Similarly, human left ventricular tissue samples from patients who died of acute MI show higher EMC10 expression compared to those from patients who died of non-cardiac causes .

The primary cellular sources of EMC10 in the infarcted heart are Ly6Chigh monocytes and Ly6Clow monocytes or macrophages, with both isoforms showing similar expression levels. Other inflammatory cell types and endothelial cells express EMC10 to a much lesser extent .

What types of antibodies against EMC10 are available for research applications?

Based on published research, several types of EMC10 antibodies have been successfully used:

• Polyclonal antibodies: The most well-documented is a polyclonal antibody raised against a peptide sequence (amino acids 208–221) that is shared by both EMC10-1 and EMC10-2 isoforms in both human and mouse proteins. This antibody was generated in rabbits and purified by reversed-phase high-performance liquid chromatography .

• Isoform-specific antibodies: These can be developed to target unique regions of either EMC10-1 (targeting the membrane-spanning domain) or EMC10-2.

• Species-specific antibodies: Antibodies specifically targeting either human EMC10 or mouse Emc10 are available, although the high sequence homology (92%) between species may result in cross-reactivity.

For most research applications, the selection should be guided by the specific experimental requirements, including the need to distinguish between isoforms and the intended application (western blotting, immunohistochemistry, flow cytometry, etc.).

What are the essential validation steps for EMC10 antibodies before use in critical experiments?

Proper validation of EMC10 antibodies should include:

• Specificity testing using knockout controls: Researchers have validated antibody specificity by demonstrating absence of immunofluorescence signal in tissues from Emc10 knockout mice .

• Recombinant protein controls: Testing the antibody against purified recombinant EMC10 protein.

• Expression system validation: Testing antibody recognition of overexpressed EMC10 in systems like HEK-293 cells transfected with EMC10-1 or EMC10-2 expression plasmids .

• Application-specific validation: For each intended application (western blotting, immunohistochemistry, immunoprecipitation, etc.), separate validation is recommended.

• Cross-reactivity assessment: If working across species, determine whether the antibody recognizes both human EMC10 and mouse Emc10 with similar efficiency.

• Isoform discrimination: Verify whether the antibody can distinguish between EMC10-1 and EMC10-2 or recognizes both isoforms.

Documentation of these validation steps is crucial for ensuring reproducible and reliable experimental results.

What are the optimal protocols for using EMC10 antibodies in immunoblotting experiments?

For successful immunoblotting of EMC10:

• Sample preparation:

  • For cell lysates: Use RIPA buffer supplemented with protease inhibitors

  • For tissue samples: Homogenize in RIPA buffer, followed by centrifugation to remove debris

  • For detection of secreted EMC10-2: Concentrate cell culture supernatants using centrifugal filters (e.g., Amicon Ultra-4)

• Protein separation:

  • Use 10-12% SDS-PAGE gels

  • Note that EMC10-2 may generate multiple bands due to heavy glycosylation as it moves through the secretory pathway

• Transfer and blocking:

  • Standard wet transfer to PVDF or nitrocellulose membranes

  • Block with 5% non-fat milk or BSA in TBS-T

• Primary antibody incubation:

  • Dilute the EMC10 antibody according to manufacturer's recommendations (typically 1:1000 to 1:5000)

  • Incubate overnight at 4°C

• Detection:

  • Use appropriate HRP-conjugated secondary antibodies

  • Include proper controls, such as GAPDH for cell lysates to exclude cell lysis when examining secreted proteins

Remember that detection of heavily glycosylated EMC10-2 may result in multiple bands of varying molecular weights.

How can EMC10 antibodies be effectively utilized in immunohistochemistry and immunofluorescence studies?

For immunohistochemistry and immunofluorescence:

• Tissue preparation:

  • Fix tissues in 4% paraformaldehyde

  • For paraffin sections: Standard embedding and sectioning, followed by deparaffinization and antigen retrieval

  • For frozen sections: Optimal cutting temperature compound embedding, cryosectioning, and fixation

• Blocking and permeabilization:

  • Block with 5-10% normal serum from the species of the secondary antibody

  • For intracellular staining, permeabilize with 0.1-0.3% Triton X-100

• Primary antibody incubation:

  • Dilute EMC10 antibody (typically 1:100 to 1:500)

  • Incubate overnight at 4°C

• Co-staining options:

  • For identifying EMC10-expressing macrophages: Co-stain with F4/80 (macrophage marker)

  • For endothelial cells: Co-stain with CD31

  • For monocyte subpopulations: Co-stain with Ly6C

• Signal detection:

  • Use appropriate fluorophore-conjugated secondary antibodies for immunofluorescence

  • For confocal microscopy, select fluorophores with minimal spectral overlap

• Controls:

  • Include tissue from EMC10 knockout animals as negative controls

  • Include positive controls from tissues known to express EMC10 (e.g., infarcted cardiac tissue)

For optimal results, always include appropriate controls and validate staining patterns with alternative methods.

What are the recommended approaches for using EMC10 antibodies in flow cytometry?

For flow cytometric analysis of EMC10-expressing cells:

• Cell preparation:

  • For tissue samples: Generate single-cell suspensions using tissue-specific enzymatic digestion protocols

  • For blood samples: Use standard isolation techniques for peripheral blood mononuclear cells

• Surface marker staining:

  • First stain for surface markers (e.g., Ly6C, F4/80) to identify relevant cell populations

  • Fix cells with 2-4% paraformaldehyde

• EMC10 staining:

  • Permeabilize cells with 0.1% saponin or similar agent

  • Incubate with EMC10 antibody at optimized concentration

  • Wash and incubate with appropriate fluorophore-conjugated secondary antibody

• Gating strategy:

  • First gate on viable single cells

  • Identify specific populations (e.g., monocytes, macrophages)

  • Analyze EMC10 expression within these populations

• Controls:

  • Include fluorescence minus one (FMO) controls

  • Use cells from EMC10 knockout animals as negative controls

  • Include isotype control antibodies

This approach enables quantitative assessment of EMC10 expression in specific cell populations, such as the Ly6Chigh monocytes and Ly6Clow monocytes/macrophages that have been identified as primary producers of EMC10 after myocardial infarction .

How can EMC10 antibodies be used to investigate the signaling pathways regulated by EMC10?

EMC10 antibodies can be valuable tools for investigating EMC10-mediated signaling pathways:

• Immunoprecipitation and co-immunoprecipitation:

  • Use EMC10 antibodies to pull down EMC10 and associated proteins

  • Identify potential receptors or binding partners that mediate EMC10 signaling

  • Investigate interactions with small GTPases (CDC42, RAC1) and downstream effectors

• Phospho-protein analysis:

  • After EMC10 stimulation, use phospho-specific antibodies to detect activation of:

    • p38 MAPK pathway components

    • MAPK-activated protein kinase 2 (MK2)

    • Heat shock protein B1 (HSPB1)

• Inhibitor studies:

  • Combine EMC10 antibody neutralization with specific pathway inhibitors (e.g., SB203580 for p38 MAPK, ML141 for CDC42)

  • Assess effects on downstream signaling events and biological outcomes

• Receptor identification:

  • Use EMC10 antibodies to block potential binding sites

  • Employ crosslinking approaches with labeled EMC10 to identify receptors

These approaches can help elucidate the still-unknown receptor through which EMC10 signals and further characterize the downstream pathways that mediate its angiogenic effects .

What experimental designs can evaluate the therapeutic potential of EMC10 in cardiovascular disease models?

Based on current knowledge of EMC10's role in angiogenesis and cardiac repair, several experimental approaches can be considered:

• Recombinant protein therapy:

  • Administer recombinant EMC10 via osmotic minipumps after myocardial infarction

  • Assess effects on:

    • Capillarization of the infarct border zone

    • Left ventricular remodeling

    • Cardiac function via echocardiography

• Cell-based therapy optimization:

  • Engineer bone marrow cells to overexpress EMC10

  • Transplant these cells into infarcted hearts

  • Compare with standard bone marrow cell therapy

• Combination therapy approaches:

  • Combine EMC10 with other known angiogenic factors (e.g., VEGF)

  • Assess potential synergistic effects on vascular repair

• Targeted antibody applications:

  • Use EMC10 antibodies conjugated to nanoparticles for targeted delivery to the heart

  • Explore antibody-based detection of circulating EMC10 as a biomarker for MI

• Follow-up studies in relevant models:

  • Test in heart failure-prone models (e.g., FVB/N mice)

  • Evaluate in large animal models of myocardial infarction

  • Consider comorbidities like diabetes or hypertension

Each approach should include appropriate controls and comprehensive assessment of cardiac structure, function, and vascular density.

How can EMC10 knockout models be utilized alongside EMC10 antibodies to understand its physiological roles?

Combining EMC10 knockout models with antibody-based approaches provides powerful insights:

• Tissue-specific expression analysis:

  • Use EMC10 antibodies for immunohistochemistry in wild-type tissues

  • Compare with knockout tissues as specificity controls

  • Map expression patterns across different tissues and developmental stages

• Bone marrow chimera experiments:

  • Create chimeric mice by transplanting wild-type bone marrow into EMC10 knockout mice

  • Use EMC10 antibodies to confirm expression in bone marrow-derived cells

  • Assess functional rescue of angiogenic defects and left ventricular remodeling

• Loss-of-function and rescue studies:

  • Document phenotypes in EMC10 knockout mice after pathological challenges

  • Administer recombinant EMC10 to rescue phenotypes

  • Use EMC10 antibodies to confirm protein delivery and localization

• Cell-autonomous vs. non-cell-autonomous effects:

  • Isolate cells from wild-type and knockout mice

  • Culture in various combinations with and without EMC10 neutralizing antibodies

  • Assess paracrine signaling between different cell populations

The Emc10 knockout mouse model has been particularly valuable in demonstrating that while there is no cardiovascular phenotype at baseline, after myocardial infarction these mice develop impaired capillarization of the infarct border zone and more pronounced left ventricular remodeling .

What are common challenges when detecting EMC10 in western blots and how can they be addressed?

Several technical challenges may arise when detecting EMC10 by western blotting:

• Multiple banding patterns:

  • Challenge: EMC10-2 is heavily glycosylated and generates multiple bands

  • Solution: Treat samples with glycosidases to confirm glycosylation-dependent banding patterns

• Low signal intensity:

  • Challenge: Endogenous EMC10 levels may be low in certain tissues

  • Solution: Concentrate samples (for secreted proteins) or use enhanced chemiluminescence detection systems

• Size verification:

  • Challenge: Confirming band identity in the absence of knockout controls

  • Solution: Use recombinant EMC10 protein as a positive control and size reference

• Isoform discrimination:

  • Challenge: Distinguishing between EMC10-1 and EMC10-2

  • Solution: Use isoform-specific antibodies if available, or analyze both cell lysates and concentrated culture supernatants (EMC10-2 should be present in supernatants)

• Cross-reactivity:

  • Challenge: Antibody cross-reactivity with other proteins

  • Solution: Validate with knockout tissues/cells and peptide competition assays

For optimal results, researchers should optimize protein extraction, separation, and transfer conditions specifically for EMC10 detection.

What controls are essential when using EMC10 antibodies for functional neutralization experiments?

When using EMC10 antibodies to neutralize protein function:

• Antibody specificity controls:

  • Use isotype-matched control antibodies at equivalent concentrations

  • Include Fab fragments or F(ab')2 fragments to exclude Fc-mediated effects

• Dose-response assessment:

  • Test multiple antibody concentrations to establish dose-dependent neutralization

  • Document complete inhibition at saturating concentrations

• Rescue experiments:

  • Add excess recombinant EMC10 to overcome antibody neutralization

  • Confirm restoration of biological activity

• Functional validation:

  • Confirm that the antibody blocks known EMC10 activities (e.g., endothelial cell migration, proliferation, or network formation)

• Specificity verification:

  • Test the antibody on cells or tissues lacking EMC10 to confirm absence of off-target effects

  • Use multiple antibodies targeting different epitopes to corroborate results

The neutralizing capacity of antibodies has been demonstrated in experiments where addition of polyclonal EMC10 antibody to culture medium abrogated the angiogenic effects of both EMC10 isoforms in scratch assays .

How might EMC10 antibodies contribute to developing novel therapeutic approaches for cardiovascular diseases?

EMC10 antibodies could facilitate several therapeutic development paths:

• Diagnostic applications:

  • Develop ELISA or other immunoassays to measure circulating EMC10 levels

  • Evaluate EMC10 as a biomarker for myocardial infarction and heart failure progression

• Targeted therapy development:

  • Use antibodies to identify the receptor(s) through which EMC10 signals

  • Develop agonists targeting these receptors to mimic EMC10's beneficial effects

• Monitoring therapeutic response:

  • Track EMC10 expression changes during experimental therapies

  • Correlate with cardiac repair and functional outcomes

• Therapeutic antibody engineering:

  • Develop bispecific antibodies linking EMC10 to other beneficial factors

  • Create antibody-drug conjugates for targeted delivery to the infarcted heart

• Cell therapy enhancement:

  • Use antibodies to identify and isolate EMC10-expressing monocyte/macrophage populations

  • Engineer these cells for enhanced therapeutic potential

Given that EMC10 has been shown to enhance infarct border-zone capillarization and exert sustained beneficial effects on left ventricular remodeling , these approaches could lead to novel therapeutic strategies for improving outcomes after myocardial infarction.

What are the most promising areas for further research on EMC10's molecular mechanisms and physiological functions?

Several research directions merit further investigation:

• Receptor identification:

  • Identify the still-unknown receptor(s) through which EMC10 signals

  • Characterize receptor distribution and regulation in cardiovascular tissues

• Signaling pathway integration:

  • Elucidate how EMC10 signaling integrates with other angiogenic pathways

  • Explore potential synergistic or antagonistic interactions with established factors like VEGF

• Non-cardiovascular functions:

  • Investigate EMC10's roles in other tissues and biological contexts

  • Explore potential functions in development, wound healing, and other disease states

• Structure-function relationships:

  • Determine critical domains for EMC10's biological activities

  • Develop optimized recombinant variants with enhanced therapeutic properties

• Immune cell regulation:

  • Further characterize EMC10's expression and function in different immune cell populations

  • Explore possible immunomodulatory roles beyond angiogenesis

This research could substantially extend our understanding of EMC10 biology beyond its established role in cardiac angiogenesis and repair after myocardial infarction .